Ixazomib

5:19
COVID-19: adapting to managing patients with MM
Joshua Richter
1:36
TOURMALINE-AL1: ixazomib-dexamethasone for AL amyloidosis
Ashutosh Wechalekar
3:36
TOURMALINE-AL1: ixazomib for AL amyloidosis
Angela Dispenzieri
1:44
Bendamustine with dexamethasone in R/R systemic AL amyloidosis
Raymond Comenzo
4:47
TOURMALINE-MM4: oral ixazomib maintenance for myeloma
Paul Richardson
1:50
ANDROMEDA: daratumumab & CyBorD for newly diagnosed AL amyloidosis
Ashutosh Wechalekar
4:23
Proteasome inhibitors in myeloma treatment
Rakesh Popat
2:48
Bortezomib maintenance with dex post-transplant for high-risk myeloma
Elena Zamagni
1:33
TOURMALINE-MM3: undetectable MRD as an endpoint for maintenance therapy
Bruno Paiva
4:23
AGMT_MM-1: the oral microbiome as a predictor of PFS in R/R myeloma
Heinz Ludwig
3:14
UVEA-IXA: ixazomib-based therapy in R/R myeloma treated via European early access program
Heinz Ludwig
2:54
TOURMALINE-MM4: oral ixazomib maintenance for myeloma
Meletios Dimopoulos
4:00
Positive learnings in myeloma management to come out of COVID-19 pandemic
Mohamad Mohty
8:13
Proteasome inhibitors: key drugs in multiple myeloma
Maria-Victoria Mateos
2:44
Myeloma QoL through induction and maintenance
Heinz Ludwig
0:55
Key amyloidosis data from ASH 2019
Morie Gertz
VJHemOnc VJHemOnc is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter

Subscribe now
The content of VJHemOnc is intended for healthcare professionals